News
Filter By:
- All
- Blog
- In the News
- Press Releases
- Publications
- All
- Blog
- In the News
- Press Releases
- Publications
Dyno Therapeutics Launches the Dyno bCap 1™ Capsid Product, a Breakthrough CNS Gene Delivery Vector Created with Generative Artificial Intelligence
– Dyno bCap 1 exhibits 100x improvement versus AAV9 in delivery to the central nervous system (CNS) and 10x detargeting of liver after intravenous (IV) …
Dyno Therapeutics to Present New Data on Optimized AAV Capsids with Transformative Therapeutic Delivery Potential at 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
WATERTOWN, Mass., May 2, 2023 – Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineering AAV capsids that can expand the …
Dyno is scaling gene therapy research with cloud-native tools like Argo Workflows and Hera
Cloud native tools such as Kubernetes and Argo Workflows are improving productivity, accelerating innovation, and increasing operational efficiency. These tools reduce the burden of infrastructure …
Leadership Updates
BOSTON, MA — April 25, 2023— We are pleased to announce the promotion of Adam Poulin-Kerstien, JD, PhD to General Counsel & appointment of Adrian Veres, …
Dyno Therapeutics Named on the Forbes List of America’s Best Startup Employers 2022
BOSTON, MA — March 11, 2022— Dyno Therapeutics is pleased to announce it has been recognized on the Forbes list of America’s Best Startup Employers 2022. …
Hera – the missing Argo Workflows Python SDK
At Dyno, we believe in collective innovation on our journey of empowering a diverse team of the best problem solvers to drive cutting edge science …
Dyno Therapeutics at Goldman Sachs Byte-ology Conference
Discussing the Convergence of Biotechnology and Technology Boston, Dec. 9, 2021 – Dyno Therapeutics announced today that management is scheduled to participate at the Goldman …
Dyno Therapeutics Named Emerging Company of the Year at New England Venture Capital Association’s 2021 NEVY Awards
BOSTON, MA — December 6, 2021— Dyno Therapeutics has announced it was selected for the Emerging Company of the Year Award in the Life …
Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle
Dyno receives $18 million upfront and is eligible for milestone and royalty payments potentially exceeding $1.6 billion TOKYO and CAMBRIDGE, Mass., Dec. 2, 2021 – Astellas Pharma Inc. (TSE: …
Our Focus on Mission Driven Collective Innovation
Dyno empowers a diverse team of the best problem-solvers to drive cutting-edge science toward improving patient health. Our mission is to build the ideal capsid …
The Endpoints 11: They’ve got mad money and huge ambitions. It’s time to go big or go home
These days, selecting a group of private biotechs for the Endpoints 11 spotlight begins with a sprint to get ahead of IPOs and the M&A teams at Big Pharma.
Introduction to AAV as a Gene Therapy Vector, Part 2
What are AAVs? and what makes them good candidates for gene therapy? By: Christopher Reardon, Stephen Malina, and Eryney Marrogi Introduction In the first part …
Meet the 24 biotech startups that top VCs say are poised to take off in the next 12 months
Every day seems to bring a fundraising record and a new company launching in the biotech industry. Insider spoke with some of the smartest and most plugged-in venture capitalists in biotech to pinpoint the most exciting startups.
Introduction to AAV as a Gene Therapy Vector, Part 1
What are AAVs? and what makes them good candidates for gene therapy? By: Stephen Malina, Eryney Marrogi, and Christopher Reardon. In two previous posts, we …
Delivering an experience our AAViators expect through Agile work practices
At Dyno, we are empowering a diverse team of the best problem-solvers to drive cutting-edge science toward improving patient health. This is easy to say …
